B. Hadley Wilson

3 weeks ago | healio.com | Erik Swain |Katie Kalvaitis |B. Hadley Wilson |Rajesh K. Kharbanda

• Routine cerebral embolic protection did not reduce stroke in patients undergoing transcatheter aortic valve replacement. • The future of routine cerebral embolic protection in TAVR is in question. CHICAGO — Routine cerebral embolic protection did not reduce the incidence of stroke at 72 hours in patients undergoing transcatheter aortic valve replacement, according to results of the BHF PROTECT-TAVI trial.

3 weeks ago | healio.com | Erik Swain |Richard Smith |B. Hadley Wilson |Michael Reardon

TAVR remains noninferior to surgery for low-risk patients at 5 years• At 5 years, there was no difference in death or disabling stroke between transcatheter aortic valve replacement and surgery in patients at low surgical risk. • Both groups had improvements in quality of life.

Oct 29, 2024 | healio.com | Erik Swain |Richard Smith |B. Hadley Wilson |JoAnn Lindenfeld

B. Hadley Wilson, MD, FACC The key message here is that it does appear beneficial to consider doing TAVR on patients with moderate aortic stenosis and HFrEF. Two reasons that came out were that the TAVR group did better on the KCCQ score and reported symptomatic improvements, and that in the surveillance group, by 2 to 3 years, the majority of patients either underwent TAVR or expired.

Apr 6, 2024 | healio.com | Erik Swain |Richard Smith |B. Hadley Wilson

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: One priority for the American College of Cardiology is getting an independent board for CV medicine. Another is further integrating health equity issues in education and training of cardiologists.

Oct 25, 2023 | notiulti.com | B. Hadley Wilson

No pudimos procesar su solicitud. Por favor, inténtelo de nuevo más tarde. Si continúa teniendo este problema, comuníquese con . Conclusiones clave:La monoterapia con ticagrelor después de menos de 1 mes de terapia antiplaquetaria dual no fue inferior a la DAPT de 12 meses para pacientes con SCA que recibieron un stent liberador de fármaco. Se suspendió la aspirina después de una media de 16 días.